Collegium Pharmaceutical Files 8-K Report

TL;DR

Collegium Pharma filed an 8-K on 5/13/24, standard corporate update.

AI Summary

On May 13, 2024, Collegium Pharmaceutical, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and does not detail specific transactions or financial figures within the provided text. The report confirms the company's legal name, incorporation in Virginia, and principal executive offices in Stoughton, MA.

Why It Matters

This 8-K filing serves as an official notification to the SEC and investors about significant company events, though the specific nature of these events is not detailed in the provided excerpt.

Risk Assessment

Risk Level: low — The provided text is a standard SEC filing notification and does not contain information that inherently increases risk.

Key Players & Entities

• COLLEGIUM PHARMACEUTICAL, INC. (company) — Registrant
• May 13, 2024 (date) — Date of earliest event reported
• Virginia (jurisdiction) — State of Incorporation
• Stoughton, MA (location) — Address of principal executive offices

FAQ

Key Financial Figures

• $0.001 — ch registered Common stock, par value $0.001 per share COLL The NASDAQ Global Sele
• $35 million — ment") with Jefferies LLC to repurchase $35 million of the Company's common stock. The ASR
• $150 million — Agreement was undertaken as part of the $150 million share repurchase program authorized by
• $31.50 — elivery of 888,889 shares, based on the $31.50 closing stock price of Collegium's comm

Filing Documents

• tm2414016d3_8k.htm (8-K) — 24KB
• 0001104659-24-060235.txt ( ) — 194KB
• coll-20240513.xsd (EX-101.SCH) — 3KB
• coll-20240513_lab.xml (EX-101.LAB) — 33KB
• coll-20240513_pre.xml (EX-101.PRE) — 22KB
• tm2414016d3_8k_htm.xml (XML) — 4KB

Forward-Looking Statements

Forward-Looking Statements To the extent that the information in this Current Report on Form 8-K are not descriptions of historical facts regarding the Company, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Examples of forward-looking statements contained in this Form 8-K include, among others, statements about the share repurchase program, the transactions under the ASR and the expected completion date of the ASR. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results, performance, or achievements to differ materially from the company's current expectations, including risks relating to, among others: developments or changes in the securities markets and fluctuations in the trading volume and market price of the Company's common stock and other risks described under the heading "Risk Factors" in the Company's Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q and other filings with the SEC. Any forward-looking statements that we make in this Form 8-K speak only as of the date of this Form 8-K. The Company assumes no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this Form 8-K.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: May 13, 2024 Collegium Pharmaceutical, Inc. By: /s/ Colleen Tupper Name: Colleen Tupper Title: Executive Vice President and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR